Literature DB >> 10100007

Synergistic role of nitric oxide and progesterone during the establishment of pregnancy in the rat.

K Chwalisz1, E Winterhager, T Thienel, R E Garfield.   

Abstract

Successful pregnancy is strictly dependent on the trophoblast-decidual interaction and on an adequate blood supply to the implantation sites. Nitric oxide (NO) has been shown to play an important role during advanced gestation, although its role during early pregnancy is unclear. The aim of the present study in rats was to evaluate whether NO plays a role during the preimplantation [days 1-4 post coitum (p.c.)] and peri-implantation (days 6-8 p.c.) phases of pregnancy. The rats were treated with the non-specific nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME), and the iNOS inhibitor aminoguanidine in the presence and absence of low-dose antiprogestin, onapristone, and evaluated on days 9 p.c. and 19 p.c., respectively. Before implantation, the treatments alone (L-NAME, aminoguanidine, onapristone) had little effect on pregnancy outcome. Conversely, aminoguanidine plus onapristone treatment completely prevented pregnancy, whereas L-NAME plus onapristone reduced the pregnancy rate to approximately 50%. In addition, both treatments drastically reduced decidualization. Oviductal flushing experiments revealed arrest of embryo development at around the 8-cell stage after aminoguanidine plus onapristone treatment on days 1-4 p.c. Similarly, treatment during the peri-implantation period with L-NAME, aminoguanidine, and onapristone each had only marginal effects on pregnancy. However, a combination of L-NAME and onapristone, and aminoguanidine plus onapristone prevented pregnancy in 71% and 42% of dams, respectively, as determined on day 19 p.c. These treatments also markedly inhibited the decidualization process. This study demonstrates synergistic effects of NOS inhibitors and an antiprogestin in preventing pregnancy. NOS, particularly the cytokine- and progesterone-inducible iNOS, may represent a new target for novel therapeutic agents capable of promoting or inhibiting pregnancy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100007     DOI: 10.1093/humrep/14.2.542

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

Review 1.  Nitric oxide and its role in blastocyst implantation.

Authors:  Omid Khorram
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

Review 2.  Does nitric oxide play a role in maternal tolerance towards the foetus?

Authors:  A González; A S López; E Alegre; J L Alcázar; N López-Moratalla
Journal:  J Physiol Biochem       Date:  2004-09       Impact factor: 4.158

3.  Uterine vascularization and pregnancy outcome in patients undergoing intracytoplasmatic sperm injection: the role of nitric oxide.

Authors:  C Battaglia; N Persico; F Mancini; P De Iaco; Paolo Busacchi; F Facchinetti; D de Aloysio
Journal:  J Assist Reprod Genet       Date:  2006-06-14       Impact factor: 3.412

4.  Potential role of intermedin/adrenomedullin 2 in early embryonic development in rats.

Authors:  Madhu Chauhan; Rebekah Elkins; Meena Balakrishnan; Chandra Yallampalli
Journal:  Regul Pept       Date:  2011-06-02

5.  The Effects of Sugammadex on Progesterone Levels in Pregnant Rats.

Authors:  Tayfun Et; Ahmet Topal; Atilla Erol; Aybars Tavlan; Alper Kılıçaslan; Sema Tuncer Uzun
Journal:  Balkan Med J       Date:  2015-04-01       Impact factor: 2.021

6.  Embryonic production of nitric oxide and its role in implantation: a pilot study.

Authors:  C Battaglia; P Ciotti; L Notarangelo; R Fratto; F Facchinetti; D de Aloysio
Journal:  J Assist Reprod Genet       Date:  2003-11       Impact factor: 3.412

7.  Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth.

Authors:  Tracy A Manuck; Lisa Smeester; Elizabeth M Martin; Martha S Tomlinson; Christina Smith; Michael W Varner; Rebecca C Fry
Journal:  Am J Perinatol       Date:  2017-12-14       Impact factor: 1.862

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.